Claims for Patent: 11,318,121
✉ Email this page to a colleague
Summary for Patent: 11,318,121
Title: | PSMA binding ligand-linker conjugates and methods for using |
Abstract: | Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them. |
Inventor(s): | Low; Philip Stewart (West Lafayette, IN), Kularatne; Sumith A. (West Lafayette, IN) |
Assignee: | Purdue Research Foundation (West Lafayette, IN) |
Application Number: | 17/359,314 |
Patent Claims: |
1. A compound of the formula B-L-C or a salt thereof, wherein B is a urea of two amino acids, wherein the two amino acids are each independently selected from the group
consisting of asparagine, aspartic acid, cysteine, glutamic acid, lysine, glutamine, arginine, serine, ornithine, and threonine; L is a divalent linker of between about 7 and about 20 atoms in length, comprising (i) a divalent alkylene group, (ii) a
divalent cycloalkylenecarbonyl group, and (iii) a divalent alkylenecarbonyl group substituted with an arylalkyl side chain; C comprises a chelating group of the formula ##STR00104## wherein * represents the point of covalent attachment of the chelating
group to L; and provided that L has a single arylalkyl side chain.
2. The compound of claim 1, or a salt thereof, wherein L further comprises a second divalent alkylenecarbonyl group. 3. The compound of claim 2, or a salt thereof, wherein L is covalently bound to B through an amide bond. 4. The compound of claim 2, or a salt thereof, wherein the compound further comprises a radioactive isotope of a metal coordinated to the chelating group. 5. The compound of claim 4, or a salt thereof, wherein L is covalently bound to B through an amide bond. 6. The compound of claim 2, or a salt thereof, wherein L is covalently bound to the chelating group through a carbon-nitrogen single bond. 7. The compound of claim 6, or a salt thereof, wherein L is covalently bound to B through an amide bond. 8. The compound of claim 6, or a salt thereof, wherein the compound further comprises a radioactive isotope of a metal coordinated to the chelating group. 9. The compound of claim 8, or a salt thereof, wherein L is covalently bound to B through an amide bond. 10. The compound of claim 1, or a salt thereof, wherein the compound further comprises a radioactive isotope of a metal coordinated to the chelating group. 11. The compound of claim 10, or a salt thereof, wherein L is covalently bound to B through an amide bond. 12. The compound of claim 10, or a salt thereof, wherein L is covalently bound to C through an amide bond. 13. The compound of claim 12, or a salt thereof, wherein L is covalently bound to B through an amide bond. 14. The compound of claim 1, or a salt thereof, wherein L is covalently bound to C through an amide bond. 15. The compound of claim 14, or a salt thereof, wherein L is covalently bound to B through an amide bond. 16. The compound of claim 1, or a salt thereof, wherein L is covalently bound to B through an amide bond. 17. A composition comprising (a) a compound of the formula B-L-C or a salt thereof, wherein B is a urea of two amino acids, wherein the two amino acids are each independently selected from the group consisting of asparagine, aspartic acid, cysteine, glutamic acid, lysine, glutamine, arginine, serine, ornithine, and threonine; L is a divalent linker of about 7 to about 20 atoms in length, comprising (i) a divalent alkylene group, (ii) a divalent cycloalkylenecarbonyl group, and (iii) a divalent alkylenecarbonyl group substituted with an arylalkyl side chain; C comprises a chelating group of the formula ##STR00105## wherein * represents the point of covalent attachment of the chelating group to L; provided that L has a single arylalkyl side chain, and (b) optionally, a component selected from the group consisting of carriers, diluents, and excipients, and combinations thereof. 18. The composition of claim 17, wherein the composition is a reconstitutable lyophilizate. 19. The composition of claim 17, wherein the compound or a salt thereof further comprises a radioactive isotope of a metal coordinated to the chelating group. 20. The composition of claim 17, wherein the composition is a pharmaceutical composition. 21. The composition of claim 19, wherein the composition is a pharmaceutical composition. 22. The composition of claim 21, comprising a carrier that comprises an aqueous solution, and wherein L further comprises a second divalent alkylenecarbonyl group and L is covalently bound to the chelating group through a carbon-nitrogen single bond. 23. The composition of claim 17, wherein L further comprises a second divalent alkylenecarbonyl group and L is covalently bound to the chelating group through a carbon-nitrogen single bond. 24. The composition of claim 19, wherein L further comprises a second divalent alkylenecarbonyl group, L is covalently bound to the chelating group through a carbon-nitrogen single bond, and the composition is a pharmaceutical composition. 25. The composition of claim 17, wherein (i) L is covalently bound to C through an amide bond, and (ii) L is covalently bound to B through an amide bond. 26. The composition of claim 19, wherein (i) L is covalently bound to C through an amide bond, and (ii) L is covalently bound to B through an amide bond. 27. The composition of claim 20, wherein (i) L is covalently bound to C through an amide bond, and (ii) L is covalently bound to B through an amide bond. 28. The composition of claim 21, wherein (i) L is covalently bound to C through an amide bond, and (ii) L is covalently bound to B through an amide bond. 29. A method for treating a disease involving a pathogenic cell population expressing PSMA, the method comprising the step of administering to a patient in need of such treatment a therapeutically effective amount of the compound of claim 4, or a salt thereof. 30. A method for treating a disease involving a pathogenic cell population expressing PSMA, the method comprising the step of administering to a patient in need of such treatment a therapeutically effective amount of the composition of claim 21. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.